about
The Structure of Carbonic Anhydrase IX Is Adapted for Low-pH CatalysisPhotodynamic therapy: one step ahead with self-assembled nanoparticlesHypoxia and VEGF mRNA expression in human tumorsHypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatmentNitric oxide production by tumour tissue: impact on the response to photodynamic therapy.Hypoxia modulates cyclin and cytokine expression and inhibits peripheral mononuclear cell proliferation.Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478.Dynamic measurements of hexafluoromisonidazole (CCI-103F) retention in mouse tumours by 1H/19F magnetic resonance spectroscopy.Efficacy of pEgr-1-endostatin combined with ionizing radiation on hypoxic conditions in nude mice bearing SKOV3 ovarian carcinoma.Solid MRI contrast agents for long-term, quantitative in vivo oxygen sensing.FBP1 expression is associated with basal-like breast carcinomaADC response to radiation therapy correlates with induced changes in radiosensitivity.Hypoxia/reoxygenation-induced mutations in mammalian cells detected by the flow cytometry mutation assay and characterized by mutant spectrum.Laboratory blood data have a significant impact on tumor response and outcome in preoperative chemoradiotherapy for advanced rectal cancer.1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine: an anticancer agent targeting hypoxic cells.Applications of magnetic resonance in model systems: cancer therapeuticsStructural insights into carbonic anhydrase IX isoform specificity of carbohydrate-based sulfamates.Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF.The evolution of diverse biological responses to DNA damage: insights from yeast and p53.Hypoxia-induced human endonuclease G expression suppresses tumor growth in a xenograft model.Tumor hypoxia and genetic alterations in sporadic cancers.Hypoxia and radiation therapy: past history, ongoing research, and future promise.Saccharin: a lead compound for structure-based drug design of carbonic anhydrase IX inhibitors.1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine (KS119): a cytotoxic prodrug with two stable conformations differing in biological and physical propertiesPhotoactivation switch from type II to type I reactions by electron-rich micelles for improved photodynamic therapy of cancer cells under hypoxiaRe-oxygenation causes hypoxic tumor regression through restoration of p53 wild-type conformation and post-translational modificationsSR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.A sucrose-binding site provides a lead towards an isoform-specific inhibitor of the cancer-associated enzyme carbonic anhydrase IX.Hypoxia-inducible factor 1alpha in oral cancer.Molecular analysis of selected cell cycle regulatory proteins during aerobic and hypoxic maintenance of human ovarian carcinoma cellsOverexpression of hypoxia-inducible-factor 1alpha(HIF-1alpha) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stageHypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status.Magnetic resonance imaging of human melanoma xenografts in vivo: proton spin-lattice and spin-spin relaxation times versus fractional tumour water content and fraction of necrotic tumour tissue.Preclinical evaluation of Laromustine for use in combination with radiation therapy in the treatment of solid tumorsGlucose deprivation is associated with Chk1 degradation through the ubiquitin-proteasome pathway and effective checkpoint response to replication blocksThe biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness.Assessing Tumor Oxygenation for Predicting Outcome in Radiation Oncology: A Review of Studies Correlating Tumor Hypoxic Status and Outcome in the Preclinical and Clinical SettingsHypoxia-responsive ionizable liposome delivery siRNA for glioma therapy.Imaging tumour physiology and vasculature to predict and assess response to heat.Prolyl hydroxylase and hypoxia inducible factor: potential targets for cancer therapy.
P2860
Q27721070-244398EB-2F77-4A01-9C6B-97ACE92FF2D6Q28083513-2A17DC69-DBC9-42B4-8183-3EFD7EECA48FQ28344471-D6F617AA-66BD-4CAF-9716-479F72C1EC6CQ28484357-C31167B4-9E7F-4BE0-ADEB-79B9DE779999Q30650491-7E0C2122-4C91-4040-8B01-BC8D6FD1A38DQ30796626-D1D7C2AD-1120-40CB-98EA-5AD357901552Q30992467-DA08A0CA-BB98-4DD9-8C3B-1F46306FAE13Q33507417-4A4EB737-1431-40C8-9A80-E83E8B427DE7Q33598166-CFFC9551-118F-4B67-8B15-4C91C8ADFD4FQ33607091-883485D4-3E21-4857-86DD-90B2C2BA59E0Q33686009-32267424-2D79-4768-9481-28C744F128E9Q33689750-644EA2F9-442A-4D74-9F5C-7E2399F8368CQ33765194-8BA6CD2D-0165-4442-BC12-5522F8C07482Q33834316-4B2656D5-CF7E-43C5-BF21-F59BA70663FFQ33878851-A12CC55A-BD7F-43F3-8D66-09B606E23446Q33995811-ECC3BB93-8BA7-4226-8018-3802F3CC0985Q34394097-CCA68BBF-C564-4D64-B547-681A94FB02B0Q34405506-16F900C0-1DFA-45FA-BB53-525E216980E5Q34487385-55A5661B-8CB1-4120-8D39-BA73D3721D87Q34679148-0E1A33D0-9730-4F35-B865-84562BCF4EA3Q34813119-F89F86FE-4D1F-4C00-A1DD-1152530C93B9Q34986265-79D824DF-9EC8-4A69-9619-AFADD4968C4FQ35157417-80780A0C-B89C-4758-A0B9-7AB924BF1152Q35209251-DDCC8562-2DAD-478E-BF88-E19495A757EDQ35592799-DA3183AD-988C-4D9A-933E-397099BD3D22Q35865264-A13D65E8-B576-498E-B021-EAD4DD5783B9Q35976983-C7F6EB86-FB69-4F23-B24E-2867EED0B54EQ36148199-29AFEE6A-AFC7-4CB1-8656-81DB0E603804Q36191216-EF64A6B6-3DED-46BE-A5A9-4255FB30E899Q36620645-300B1D89-7CDF-487E-8D1A-AC5E67A06941Q36648412-733B728B-3DE4-496B-BAD8-C0660D58B461Q36665942-7FC4CCB5-F2B5-483C-8BFD-31FB9BE28820Q36721579-73F486E7-442E-490A-AD84-8E0EE67E7F58Q36865227-BF9F4D0E-D316-4AE2-938B-F90D5FDF4855Q37188498-A80A28CB-06D7-4AF1-8C24-AD208E32052CQ37210542-EC892C25-615C-4465-8C83-6E8C1E936294Q37604088-696A656F-A750-4F01-BDFB-07417AD0DF0DQ37641455-BF4375FE-210D-4C35-9CEB-1ECF42C6188EQ37730090-71848D9E-A116-4D41-BE73-ED218832BFC8Q37827854-7EEFBB10-0124-4508-979C-60FD909ED2DD
P2860
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh
1987年學術文章
@zh-hant
name
Tumor hypoxia: its impact on cancer therapy.
@en
Tumor hypoxia: its impact on cancer therapy.
@nl
type
label
Tumor hypoxia: its impact on cancer therapy.
@en
Tumor hypoxia: its impact on cancer therapy.
@nl
prefLabel
Tumor hypoxia: its impact on cancer therapy.
@en
Tumor hypoxia: its impact on cancer therapy.
@nl
P2860
P356
P1476
Tumor hypoxia: its impact on cancer therapy.
@en
P2093
J E Moulder
S Rockwell
P2860
P2888
P304
P356
10.1007/BF00055376
P577
1987-01-01T00:00:00Z